Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 18/20 | 0.45 |
| ▸ | CA9 | Q16790 | 14/20 | 0.45 |
| ▸ | CA12 | O43570 | 13/20 | 0.45 |
| ▸ | CA1 | P00915 | 14/20 | 0.44 |
| ▸ | CA7 | P43166 | 10/20 | 0.44 |
| ▸ | CA5A | P35218 | 9/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 9/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.44 |
| ▸ | CA6 | P23280 | 8/20 | 0.44 |
| ▸ | CA4 | P22748 | 8/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4621382 | 0.81 | CA2 (0.47) | ALDH1A1CA2CA9CA12CA1 | |
| SCHEMBL9450366 | 0.78 | CA2 (0.56) | ALDH1A1CA2CA9CA12CA1 | |
| SCHEMBL38651153 | 0.77 | NR1I2 (0.60) | ALDH1A1CA2CA9CA12CA1 | |
| SCHEMBL20032091 | 0.76 | CA2 (0.55) | ALDH1A1CA2CA9CA12CA1 | |
| SCHEMBL31010761 | 0.75 | NR1I2 (0.63) | ALDH1A1CA2CA9CA12CA1 | |
| SCHEMBL20372807 | 0.74 | NR1I2 (0.54) | ALDH1A1CA2CA9CA12CA1 | |
| SCHEMBL18713704 | 0.72 | CA2 (0.59) | ALDH1A1CA2CA9CA12CA1 | |
| SCHEMBL28246182 | 0.72 | CA2 (0.51) | ALDH1A1CA2CA9CA12CA1 | |
| SCHEMBL11730795 | 0.71 | CA2 (0.69) | CA2CA9CA12CA1CA7 | |
| SCHEMBL202948 | 0.71 | CA2 (0.81) | ALDH1A1CA2CA9CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-29 | — | — | US | disclosed |
| EP-3613729-A1 | TETRACYCLIC COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-02-26 | — | — | EP | disclosed |
| EP-3345903-B1 | TETRACYCLIC COMPOUNDS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2019-10-09 | — | — | EP | disclosed |
| EP-3345903-A1 | TETRACYCLIC COMPOUNDS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2018-07-11 | — | — | EP | disclosed |
| EP-2975024-B1 | TETRACYCLIC COMPOUNDS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-03-28 | — | — | EP | disclosed |
| US-20160340308-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-24 | — | — | US | disclosed |
| US-9440922-B2 | Tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-09-13 | — | — | US | disclosed |
| EP-2441753-B1 | TETRACYCLIC COMPOUND | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2016-03-30 | — | — | EP | disclosed |
| EP-2975024-A1 | TETRACYCLIC COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-9126931-B2 | Tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2441753-A1 | TETRACYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142119-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | ALDH1A1 1165/4885CA2 291/4885CA9 107/4885 |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | ALDH1A1 1165/4885CA2 291/4885CA9 107/4885 |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | ALDH1A1 1165/4885CA2 291/4885CA9 107/4885 |
| US-20160340308-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | ALDH1A1 1165/4885CA2 291/4885CA9 107/4885 |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | ALDH1A1 1165/4885CA2 291/4885CA9 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.